Decreasing Costs and Clinic Wait Time While Maintaining Safety for Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) for Multiple Myeloma

被引：1
|
作者：
Inyang, Eno [1 ]
Aktas-Samur, Anil [2 ]
Munshi, Nikhil C. [3 ]
Leblebjian, Hour [1 ]
机构：
[1] Dana Farber Canc Inst, Dept Pharm, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[3] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-146605
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
666
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)
    Joseph, Nisha S.
    Kaufman, Jonathan L.
    Dicamillo, Sara
    Roberts, Danielle
    Gupta, Vikas A.
    Hofmeister, Craig C.
    Dhodapkar, Madhav V.
    Boise, Lawrence H.
    Lonial, Sagar
    Nooka, Ajay K.
    BLOOD, 2023, 142
  • [22] Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse
    Montefusco, Vittorio
    Corso, Alessandro
    Galli, Monica
    Ardoino, Ilaria
    Pezzatti, Sara
    Carniti, Cristina
    Patriarca, Francesca
    Gherlinzoni, Filippo
    Zambello, Renato
    Sammassimo, Simona
    Marcatti, Magda
    Nozza, Andrea
    Crippa, Claudia
    Cafro, Anna Maria
    Baldini, Luca
    Corradini, Paolo
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (06) : 907 - 917
  • [23] Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
    Shah, Jatin J.
    Feng, Lei
    Manasanch, Elisabet E.
    Weber, Donna M.
    Thomas, Sheeba K.
    Turturro, Francesco
    Alexanian, Raymond
    Shah, Nina
    Popat, Uday R.
    Nieto, Yago
    Bashir, Qaiser
    Qazilbash, Muzaffar H.
    Champlin, Richard E.
    Orlowski, Robert Z.
    BLOOD, 2014, 124 (21)
  • [24] Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
    Shah, Jatin J.
    Feng, Lei
    Manasanch, Elisabet E.
    Weber, Donna
    Thomas, Sheeba K.
    Turturro, Francesco
    Shah, Nina
    Popat, Uday R.
    Nieto, Yago
    Bashir, Qaiser
    Munoz, Silvia C.
    Landry, Ashley
    Mendoza, Kathleen
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    Orlowski, Robert Z.
    BLOOD, 2015, 126 (23)
  • [25] A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
    O'Donnell, Elizabeth K.
    Laubach, Jacob P.
    Yee, Andrew J.
    Huff, Carol A.
    Basile, Frank G.
    Wade, Philip M., Jr.
    Paba-Prada, Claudia E.
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Couture, Nicole R.
    Doherty, Lauren
    Lyons, Hannah
    English, Caroline
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    Richardson, Paul C.
    Raje, Noopur S.
    BLOOD, 2015, 126 (23)
  • [26] Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study
    Kaufman, Jonathan L.
    Shah, Jatin J.
    Laubach, Jacob P.
    Mitchell, Alaina R.
    Sharp, Cathy
    Lewis, Colleen
    Harvey, R. Donald
    Gleason, Charise
    Casbourne, Daniela
    Nooka, Ajay K.
    Heffner, Leonard T.
    Richardson, Paul G.
    Orlowski, Robert Z.
    Lonial, Sagar
    BLOOD, 2012, 120 (21)
  • [27] Final Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD lite) in Transplant-Ineligible Multiple Myeloma
    O'Donnell, Elizabeth
    Laubach, Jacob
    Yee, Andrew J.
    Chen, Tianqi
    Huff, Carol Ann
    Basile, Frank G.
    Wade, Philip
    Paba-Prada, Claudia
    Ghobrial, Irene M.
    Schlossman, Robert
    Burke, Jill
    Cynthia, Harrington
    Lively, Kathleen
    Lyons, Hannah
    Munshi, Nikhil
    Trippa, Lorenzo
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur
    BLOOD, 2017, 130
  • [28] Three years (yrs) maintenance with bortezomib, lenalidomide, and dexamethasone (RVD) in multiple myeloma (MM): Results of Total Therapy (TT) IIIB
    Al Hadidi, Samer
    Ababneh, Obada Ehab
    Schinke, Carolina D.
    Thanendrarajan, Sharmilan
    Bailey, Clyde
    Zangari, Maurizio
    Tricot, Guido
    Shaughnessy, John D.
    Zhan, Fenghuang
    Sawyer, Jeffrey
    Barlogie, Bart
    van Rhee, Frits
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM)
    Lacy, Martha Q.
    LaPlant, Betsy R.
    Laumann, Kristina M.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Ailawadhi, Sikander
    Chanan-Khan, Asher
    Stewart, A. Keith
    Reeder, Craig B.
    Rajkumar, S. Vincent
    Mikhael, Joseph R.
    BLOOD, 2014, 124 (21)
  • [30] Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma.
    Leleu, Xavier
    Mateos, Maria-Victoria
    Jagannath, Sundar
    Delimpasi, Sosana
    Simonova, Maryana
    Spicka, Ivan
    Pour, Ludek
    Kriachok, Iryna
    Gavriatopoulou, Maria
    Dimopoulos, Meletios A.
    Pylypenko, Halyna
    Auner, Holger W.
    Reuben, Benjamin
    Venner, Christopher P.
    Garg, Mamta
    DeCastro, Andrew
    Shah, Jatin J.
    Grosicki, Sebastian
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345